- Current report filing (8-K)
November 13 2009 - 5:00PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
November 12,
2009
BIOSTAR
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Maryland
|
333-147363
|
20-5101287
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
No.
588 Shiji Avenue, Xianyang City, Shaanxi
Province, The People’s Republic of
China
|
712046
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
86-
029-33686638
Copies
to:
Benjamin
Tan, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32 Floor
New York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of Operations and Financial Condition
On
November 12, 2009, Biostar Pharmaceuticals, Inc., a Maryland corporation (the
“Company”), announced its results of operations for the three and nine months
ended September 30, 2009. A copy of the related press release is
being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference in its entirety.
The
information in this report, including Exhibit 99.1 shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “
Exchange Act
”), or
incorporated subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended (the “
Securities Act
”), and
shall not be incorporated by reference in any registration statement or other
document filed under the Securities Act or the Exchange Act, whether made before
or after the date hereof, regardless of any general incorporation language in
such filings, except as shall be expressly set forth by specific reference in
such a filing.
Item
9.01
Financial
Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
BIOSTAR PHARMACEUTICALS, INC.
Dated:
November 12, 2009
By:
/s/
Ronghua Wang
Name:
Ronghua Wang
Title:
Chief Executive Officer
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biostar Pharmaceuticals (CE) (USOTC:BSPM)
Historical Stock Chart
From Jul 2023 to Jul 2024